Conditions: Type 2 Diabetes Mellitus
Allocation:  | Intervention model: PARALLEL
Enrollment: 254
Healthy volunteers: no

Brief summary:
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin).

Detailed description:

Arms:
arm 1: Teneligliptin (20mg once daily) for 24 weeks arm 2: Placebo for 24 weeks

Interventions: intervention 1: Teneligliptin 20mg intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document:
Prot_000.pdf: 















































































































SAP_001.pdf: